To compare the performance of a professional continuous glucose monitoring (proCGM) and a personal continuous glucose monitoring (persCGM) system worn in parallel under standardized conditions in individuals with type 1 diabetes (T1D), two CGM systems (iPro2 -proCGM; Minimed 640G -persCGM) worn in parallel using the same sensor (Enlite 2) were compared. Ten and home phase (18.6 AE 26.8% vs. 17.4 AE 21.3%, P = 0.87) was observed. All sensors performed less accurately during hypoglycaemia. ProCGM and persCGM showed similar performance during daytime and night-time for the inpatient and the home phase. However, sensor performance was reduced during hypoglycaemia for both systems.
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| INTRODUCTION
In recent years, continuous glucose monitoring (CGM) has gained increasing importance in diabetes management. 1 In contrast to personal CGM (persCGM), where glucose values are displayed in real time, professional CGM (proCGM) is used intermittently in a blinded mode for a short period (e.g. 6-14 days) 2 and data are retrospectively assessed by health care professionals (HCPs) to detect patterns and adjust therapy. PersCGM showed that it improved glycaemic control (HbA1c) and reduced time spent in hypoglycaemia, [3] [4] [5] [6] [7] and proCGM-"Othmar Moser and Marlene Pandis contributed equally to this work."
supported therapy was shown to improve HbA1c in children with type 1 diabetes (T1D) and people with type 2 diabetes. 8, 9 Two studies showed that glucose patterns observed during a 14-day period of CGM are already representative of interstitial glucose patterns seen over a longer period of time (3 months 2 | METHODS
| Participants
The main inclusion criteria were diagnosis of T1D for over 6 months, intensified insulin treatment for at least 3 months, body mass index (BMI) <35 kg/m 2 and HbA1c <86 mmol/mol (<10%).
The main exclusion criteria were pregnancy, breastfeeding or females with the intention to become pregnant, the intake of any medication except insulin that significantly impacts glucose metabolism, any disease or medical condition which would interfere with the trial results, known adrenal gland disorders, pancreatic tumour or insulinoma.
| Informed consent procedure
Participants gave their written informed consent prior to any trial- 
| Inpatient phase

| Home phase
Participants continued using proCGM and persCGM in parallel for five consecutive days at home. Participants were asked to perform at least seven capillary glucose measurements at home using the studyspecific glucose meter. Additional measurements could be taken at any time if deemed necessary by the participant. No specific instructions on general diabetes management or hypoglycaemia management were given, and participants were asked to take care of their diabetes as usual. Data for capillary BG, meals and insulin injections were documented in a paper-diary. The Contour Next Link 2.4 (Bayer Pharma AG) BG meter was used for capillary BG measurements.
| Statistical analysis
Interstitial glucose values were compared with corresponding plasma (inpatient phase) or capillary (home-phase) BG values. All analyses were performed separately for the inpatient and the home phase.
Overall accuracy, accuracy during hypoglycaemia (<3.9 mmol/L), (daytime, P = 0.8318). Overall data on MARD are reported in Table 1 . 
| Home phase
During the home phase a total of 456 capillary BG measurements were performed, which is on average 8 AE 3 measurements per day. During the inpatient and the home phase, no significant difference between the two systems was observed when assessed by MARD (P > 0.05). This is true across all glycaemic ranges, as well as for nighttime and daytime (Table 1 
| DISCUSSION
Our study indicated that during the inpatient phase both systems showed similar accuracy; the performance during the home phase did not differ from the performance during the inpatient phase.
Compared with daytime, sensor performance was better for both systems at all levels of glycaemia over night, when fewer glucose fluctuations occur. Reduced sensor performance during daytime is probable because of a higher rate of change in glucose than during night-time. 16 Since real-life conditions were mimicked by means of physical exercise and premeal bolus insulin overdosing in our study, the higher rate of glucose change might have influenced sensor accuracy for both systems.
Findings from the inpatient phase seem to translate into the home phase where sensor accuracy was higher during more stable glycaemia at night compared to day, even though data on physical exercise and meals were not documented meticulously, and sampling frequency was not high enough during the home phase to perform these analyses separately for the home phase.
As expected, both CGM systems were less accurate during hypoglycaemia than during euglycaemia and hyperglycaemia. 17 The impaired accuracy during hypoglycaemia is similar to previous research investigating the performance of the persCGM system (MARD 38.8% for the lowest glucose levels). 17 It is especially worrisome that both CGM systems tend to overestimate glycaemia when compared with capillary glucose. While CGM systems seem to reliably report glycaemia in euglycaemia and hyperglycaemia, accuracy during hypoglycaemia still requires improvement, as patients might make the wrong treatment decisions if true glycaemia is lower, or more often Numerically, albeit not statistically significant, proCGM showed worse performance during hypoglycaemia than persCGM, especially during daytime at home (MARD: 49.8 AE 64.8% vs. 27.7 AE 36.0%).
These disparities in sensor performance might be attributed to the fact that one sensor is calibrated prospectively and the other one is calibrated retrospectively, which reflects different calibration algorithms. As the prospectively calibrated sensor signal is used for immediate treatment decisions, it can be assumed that its signal should be more accurate; alternatively, the sensor signal should be shut down if it is not deemed reliable, with no glucose value being indicated.
Findings from our study add knowledge on sensor performance during different levels of glycaemia during daytime and night-time over a period of 5 days. Systems were not only tested under standardized conditions during an inpatient phase but also at home, when participants followed their regular daily routines. Thus, it is worthwhile knowing, that especially during hypoglycaemia, CGM-derived data need to be questioned and may require confirmation by capillary BG measurements. This is also true for proCGM when used as a diagnostic tool, both in routine care and in outcome studies where the duration and frequency of hypoglycaemia need to be interpreted with caution. 2, 18 Some limitations of previous studies (short duration of experiment, lack of home phase, lack of sleep phase) were addressed. However, our study is limited by the rather small number of participants and the potential pressure artefacts (ie, on which side was the patient sleeping with regard to sensor performance). Another limitation is the unblinded persCGM signal that was available to the participants. As persCGM was shown to significantly reduce hypoglycaemia rates in clinical trials and routine care, 19 potential bias might have been introduced, reducing hypoglycaemia and thus limiting the time in hypoglycaemia to use for accuracy assessment.
In conclusion, in the present analysis, proCGM and persCGM showed similar performance during daytime and night-time at the Sensor performance assessed by MARD during inpatient and home phase as well as separated for daytime and night-time for overall values, hypoglycaemia (<3.9 mmol/L), euglycaemia (3.9-10.0 mmol/L) and hyperglycaemia (>10.0 mmol/L); (n) indicates the number of sensor-reference pairs available for proCGM and persCGM, respectively for statistical assistance and Sarah Bischof (Medical University of Graz) for data monitoring. We want to thank the volunteers for their participation in the study.
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